This compound, known as Capecitabine USP Impurity, is a chemically defined impurity associated with the antineoplastic drug Capecitabine. Its systematic name is [1-[5-Deoxy-3-O-(5-deoxy-d-ribofuranosyl)-d-ribofuranosyl]-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]-carbamic acid pentyl ester. It is structurally related to the active pharmaceutical ingredient (API) and is identified as a process-related or degradation impurity. As a specified impurity, its primary application is in the pharmaceutical quality control and analytical development of Capecitabine. It serves as a reference standard (impurity standard) for method validation, stability studies, and batch release testing to ensure the drug product's safety, efficacy, and compliance with pharmacopeial specifications such as the United States Pharmacopeia (USP). Monitoring and controlling this impurity is critical in the manufacturing and regulatory filing of Capecitabine formulations. The compound is of high purity and is supplied specifically for analytical purposes. Handling requires standard laboratory safety precautions for chemical reagents. Its significance lies in supporting the stringent impurity profiling required for modern oncology drugs, contributing to robust quality assurance in cancer therapy.